Sutro Biopharma Net Interest Income History

STRO Stock  USD 21.25  -0.08  -0.38%   
Sutro Biopharma's latest Net Interest Income is 16.1 M versus 15.4 M in the prior year, a 4.76% increase. Sutro Biopharma's Net Interest Income is recovering based on multi-year data. Complete Financial Overview
 
Net Interest Income  
 First Reported
2019-03-31
 Previous Quarter
-8.2 M
 Current Value
-8.4 M
 Quarterly Volatility
5.1 M
Macro event markers
 
Covid
 
Interest Hikes

Latest Sutro Biopharma's Net Interest Income Growth Pattern

The historical Net Interest Income for Sutro Biopharma spanning the full 10-year history is displayed in the chart. Sustained recovering momentum across multiple periods strengthens confidence in the directional signal. Inflection points in the chart may coincide with changes in strategy, market conditions, or accounting treatment. The pace of change matters as much as the direction when assessing Sutro Biopharma's financial trajectory. Flat stretches in Sutro Biopharma's Net Interest Income may reflect operational stability or a pause between growth phases.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

Net Interest Income Trend Statistics

Arithmetic Mean 2,532,907
Coefficient Of Variation 241.88
Mean Deviation 4,562,563
Median 251,000
Standard Deviation 6,126,674
Sample Variance37.5T
Range18.7M
R-Value 0.58
Mean Square Error26.4T
R-Squared 0.34
Significance 0.01
Slope 707,520
Total Sum of Squares600.6T

Sutro Biopharma Net Interest Income History

202616.1 M
202515.4 M
202413.4 M
2023-2.2 M
2022109 K
2021-2.6 M
2020-2.6 M
20194.1 M
2018 -7000.0
2017-339 K

Related Accounts

Last ReportedEnd Of Year Estimate
Net Interest Income15.4 M16.1 M
Interest Income51.1 M53.6 M
Interest Expense35.7 M37.5 M
Interest Coverage 4.14 4.35
Interest-Bearing Debt Per Share-2.65 -2.52

Methodology, Assumptions & Data Sources

Below you can see Sutro Biopharma's Net Interest Income across recent years. Big swings can signal sensitivity to the broader economy.

Sutro Biopharma metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Analyst inputs may be included when coverage is available. Not all fields update in real time. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Last reviewed on March 9th, 2026